IP Library Granted Patent US 11,305,275
Granted Patent B2
US 11,305,275 · App. 16/514,920 · Granted Apr 19, 2022

Bodily fluid sample collection and transport

Inventors: Elizabeth A. Holmes (San Francisco, CA); Clarissa Lui (Menlo Park, CA); Michael Chen (Sunnyvale, CA); Daniel Young (San Francisco, CA)
Assignee: Labrador Diagnostics LLC
B01L3/502A61B5/151A61B5/15003A61B5/154A61B5/150022A61B5/150099A61B5/15109A61B5/15111A61B5/15113A61B5/15186A61B5/150251A61B5/150343A61B5/150732A61B5/150755A61B5/150992B01L3/5025B01L3/527B01L3/545G01N1/38G01N1/4077G01N33/491A61B5/15117A61B5/150305A61B5/150351A61B5/150389A61B5/150503A61B5/150572A61B5/150793A61B5/150824A61B5/150954A61B5/150984B01L2200/185B01L2300/022B01L2300/044B01L2300/0672B01L2300/0832B01L2300/0864B01L2300/0877B01L2300/18B01L2300/1822B01L2400/0409G01N2001/005G01N2001/4083G01N2035/00326
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,305,275
App. No.
16/514,920
Granted
Apr 19, 2022
Kind
B2
Abstract

Bodily fluid sample collection systems, devices, and method are provided. The sample is collected at a first location and subjected to a first sample processing step. The sample may be shipped to a second location and subjected to a second sample processing step that does not introduce contaminants into a plasma portion of the sample formed from the first processing step. The sample may also be mixed with other material(s) in the collection device.

Claims (20)

1. A method comprising:

receiving, in a channel, a bodily fluid sample provided by a subject;

mixing the bodily fluid sample with an anticoagulant to generate a mixed bodily fluid sample; and

collecting, in a vessel in fluid communication with the channel, the mixed bodily fluid sample,

wherein the anticoagulant comprises EDTA, and wherein the mixed bodily fluid sample comprises a bulk concentration of EDTA no less than about 2.5 milligrams per milliliter and no greater than about 10 milligrams per milliliter, wherein a concentration of the anticoagulant coating varies along a length of the channel according to a gradient.

2. The method of claim 1 , wherein mixing the bodily fluid sample with the anticoagulant comprises mixing the bodily fluid sample with the anticoagulant without generating a local concentration of EDTA greater than about 1121110 milligrams per milliliter.

3. The method of claim 1 , wherein the mixed bodily fluid sample reaches the bulk concentration of EDTA at a time less than 90 seconds after the bodily fluid sample was initially received in the channel.

4. A method comprising:

receiving, in a channel, a bodily fluid sample provided by a subject;

mixing the bodily fluid sample with an anticoagulant to generate a mixed bodily fluid sample; and

collecting, in a vessel in fluid communication with the channel, the mixed bodily fluid sample,

wherein the anticoagulant comprises heparin, and wherein the mixed bodily fluid sample comprises a bulk concentration of heparin no less than about 20 units per milliliter and no greater than about 150 units per milliliter, wherein a thickness of the anticoagulant coating varies along a length of the channel according to a gradient.

5. The method of claim 4 , wherein the mixed bodily fluid sample reaches the bulk concentration of heparin at a time less than 90 seconds after the bodily fluid sample was initially received in the channel.

6. The method of claim 4 , wherein mixing the bodily fluid sample with the anticoagulant comprises mixing the bodily fluid sample with the anticoagulant with a shear rate no greater than about 1,000 reciprocal seconds.

7. A method comprising:

receiving, in a channel, a bodily fluid sample provided by a subject;

mixing the bodily fluid sample with an anticoagulant to generate a mixed bodily fluid sample; and

collecting, in a vessel in fluid communication with the channel, the mixed bodily fluid sample,

wherein the anticoagulant comprises EDTA, and wherein the mixed bodily fluid sample comprises a bulk concentration of EDTA no less than about 2.5 milligrams per milliliter and no greater than about 10 milligrams per milliliter, wherein a concentration of the anticoagulant coating varies along a length of the channel according to a gradient;

wherein mixing the bodily fluid sample with the anticoagulant comprises mixing the bodily fluid sample with the anticoagulant with a shear rate no greater than about 1,000 reciprocal seconds.

Assignments (3)
CHANGE OF NAME Recorded Apr 15, 2020
From: THERANOS IP COMPANY, LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052410/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2020
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 052385/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2020
From: LUI, CLARISSA; YOUNG, DANIEL; HOLMES, ELIZABETH A.; CHEN, MICHAEL
To: THERANOS, INC.
Reel/Frame 052349/0805 →
Continuity (5)
Continuation 15290248 · Oct 11, 2016
Continuation In Part 15216658 · Jul 21, 2016
Provisional Application 62239636 · Oct 9, 2015
Provisional Application 62195287 · Jul 21, 2015
Related Publication 20200047179A1 · Feb 13, 2020